{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:59:18Z","timestamp":1775278758465,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007438","name":"Familien Hede Nielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.vaccine.2015.06.087","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T21:00:56Z","timestamp":1458421256000},"page":"2147-2156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression"],"prefix":"10.1016","volume":"34","author":[{"given":"Emeline","family":"Ragonnaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie C.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders Elm","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7378","key":"10.1016\/j.vaccine.2015.06.087_bib0215","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.vaccine.2015.06.087_bib0220","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.06.087_bib0225","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/CMAR.S33979","article-title":"The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses","volume":"4","author":"Coventry","year":"2012","journal-title":"Cancer Manag Res"},{"issue":"7528","key":"10.1016\/j.vaccine.2015.06.087_bib0230","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.06.087_bib0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4 PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.087_bib0240","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.180.5.3339","article-title":"MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines","volume":"180","author":"Holst","year":"2008","journal-title":"J Immunol"},{"issue":"10 (Oct)","key":"10.1016\/j.vaccine.2015.06.087_bib0245","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/eji.200939543","article-title":"Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control","volume":"39","author":"Sorensen","year":"2009","journal-title":"Eur J Immunol"},{"issue":"41","key":"10.1016\/j.vaccine.2015.06.087_bib0250","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1016\/j.vaccine.2010.07.066","article-title":"Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model","volume":"28","author":"Sorensen","year":"2010","journal-title":"Vaccine"},{"issue":"12 (Dec)","key":"10.1016\/j.vaccine.2015.06.087_bib0255","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/mt.2014.130","article-title":"Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination","volume":"22","author":"Jensen","year":"2014","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.vaccine.2015.06.087_bib0260","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10 (Oct)","key":"10.1016\/j.vaccine.2015.06.087_bib0265","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/eji.1830231037","article-title":"Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor","volume":"23","author":"Goodwin","year":"1993","journal-title":"Eur J Immunol"},{"issue":"3 (Mar)","key":"10.1016\/j.vaccine.2015.06.087_bib0270","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/intimm\/14.3.275","article-title":"Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells","volume":"14","author":"Futagawa","year":"2002","journal-title":"Int Immunol"},{"issue":"3 (Mar)","key":"10.1016\/j.vaccine.2015.06.087_bib0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.cgt.7700670","article-title":"Role of 4-1BB:4-1BB ligand in cancer immunotherapy","volume":"11","author":"Cheuk","year":"2004","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.087_bib0280","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4049\/jimmunol.150.3.771","article-title":"Inducible T cell antigen 4-1BB analysis of expression and function","volume":"150","author":"Pollok","year":"1993","journal-title":"J Immunol"},{"issue":"2 (Jul)","key":"10.1016\/j.vaccine.2015.06.087_bib0285","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0008-8749(89)90040-3","article-title":"Expression characteristics of two potential T cell mediator genes","volume":"121","author":"Kwon","year":"1989","journal-title":"Cell Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.087_bib0290","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4049\/jimmunol.167.3.1313","article-title":"4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy","volume":"167","author":"Cannons","year":"2001","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.087_bib0295","doi-asserted-by":"crossref","first-page":"e105520","DOI":"10.1371\/journal.pone.0105520","article-title":"4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques","volume":"9","author":"Spencer","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.087_bib0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.087_bib0305","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.168.8.3755","article-title":"In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway","volume":"168","author":"Diehl","year":"2002","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2015.06.087_bib0310","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.168.10.4897","article-title":"4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function","volume":"168","author":"Wen","year":"2002","journal-title":"J Immunol"},{"issue":"5 (May)","key":"10.1016\/j.vaccine.2015.06.087_bib0315","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"6 (Jun)","key":"10.1016\/j.vaccine.2015.06.087_bib0320","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med"},{"issue":"2 (Feb)","key":"10.1016\/j.vaccine.2015.06.087_bib0325","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/mt.2009.205","article-title":"Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL","volume":"18","author":"Huang","year":"2010","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.087_bib0330","doi-asserted-by":"crossref","first-page":"e66081","DOI":"10.1371\/journal.pone.0066081","article-title":"The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies","volume":"8","author":"Jensen","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vaccine.2015.06.087_bib0335","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.4049\/jimmunol.178.7.4194","article-title":"Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice","volume":"178","author":"Niu","year":"2007","journal-title":"J Immunol"},{"issue":"37","key":"10.1016\/j.vaccine.2015.06.087_bib0340","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1016\/j.vaccine.2011.06.022","article-title":"Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease","volume":"29","author":"Moraes","year":"2011","journal-title":"Vaccine"},{"issue":"12 (Dec)","key":"10.1016\/j.vaccine.2015.06.087_bib0345","first-page":"3698","article-title":"The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors","volume":"35","author":"Janik","year":"1975","journal-title":"Cancer Res"},{"issue":"3 (Mar)","key":"10.1016\/j.vaccine.2015.06.087_bib0350","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/eji.201445174","article-title":"Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice","volume":"45","author":"Bang","year":"2015","journal-title":"Eur J Immunol"},{"issue":"5 (Nov)","key":"10.1016\/j.vaccine.2015.06.087_bib0355","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-3083.2002.01166.x","article-title":"Treatment of an immortalized APC cell line with both cytokines and LPS ensures effective T-cell activation in vitro","volume":"56","author":"Jorgensen","year":"2002","journal-title":"Scand J Immunol"},{"issue":"1 (Jul)","key":"10.1016\/j.vaccine.2015.06.087_bib0360","first-page":"243","article-title":"Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours","volume":"23","author":"Mendoza","year":"2003","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.087_bib0365","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.4049\/jimmunol.0903894","article-title":"The role of CD80\/CD86 in generation and maintenance of functional virus-specific CD8+ T cells in mice infected with lymphocytic choriomeningitis virus","volume":"185","author":"Grujic","year":"2010","journal-title":"J Immunol"},{"issue":"11 (Jun)","key":"10.1016\/j.vaccine.2015.06.087_bib0370","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1128\/JVI.00465-13","article-title":"Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation","volume":"87","author":"Steffensen","year":"2013","journal-title":"J Virol"},{"issue":"20 (Oct)","key":"10.1016\/j.vaccine.2015.06.087_bib0375","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/sj.gt.3302556","article-title":"The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma","volume":"12","author":"Xu","year":"2005","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.087_bib0380","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.4049\/jimmunol.0802597","article-title":"Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand","volume":"183","author":"Wyzgol","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.087_bib0385","doi-asserted-by":"crossref","first-page":"e0117242","DOI":"10.1371\/journal.pone.0117242","article-title":"Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection","volume":"10","author":"Holst","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2015.06.087_bib0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-065X.2010.00926.x","article-title":"Generation of effector CD8+ T cells and their conversion to memory T cells","volume":"236 (Jul)","author":"Cui","year":"2010","journal-title":"Immunol Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.087_bib0395","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2009-06-227546","article-title":"Memories that last forever: strategies for optimizing vaccine T-cell memory","volume":"115","author":"Ahlers","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.vaccine.2015.06.087_bib0400","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.4049\/jimmunol.1301723","article-title":"4-1BB ligand activates bystander dendritic cells to enhance immunization in trans","volume":"193","author":"Macdonald","year":"2014","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.087_bib0405","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.4049\/jimmunol.0900537","article-title":"Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination","volume":"184","author":"Holst","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2015.06.087_bib0410","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/ijc.28943","article-title":"Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer","volume":"135","author":"Gauttier","year":"2014","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.087_bib0415","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.06.087_bib0420","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-9-90","article-title":"Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines","volume":"9","author":"Lechner","year":"2011","journal-title":"J Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15009020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T08:30:00Z","timestamp":1692261000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15009020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":42,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0264410X15009020"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.087","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}